Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study

Introna, Martino; Borleri, Gianmaria; Conti, Elena; Franceschetti, Marta; Barbui, Anna Maria; Broady, Raewyn; Dander, Erica; Gaipa, Giuseppe; D’Amico, Giovanna; Biagi, Ettore; Parma, Matteo; Pogliani, Enrico Maria; Spinelli, Orietta; Baronciani, D; Grassi, Anna; Golay, Joseé; Barbui, Tiziano; Biondi, Andrea; Rambaldi, Alessandro

doi:10.3324/haematol.11132

Cited by 158 publications

(144 citation statements)

References 33 publications

Supporting

Mentioning

135

Contrasting

Order By: Relevance

“…Cytokine-induced killer (CIK) cells, derived from the peripheral blood of normal donors or leukemia/lymphoma patients, are T cells with a characteristic immunophenotype of CD3 and CD56 double positivity. Data show that CIK cells exhibit potent anti-tumor activity in vitro and in vivo, they do not interfere with bone marrow engraftment in vivo and have little GVHD activity in several allogeneic models [7] . In this study, we first investigate the effects of TCA on the apoptosis of K562 leukemic cells and the effect of TCA on the cytotoxicity of CIK cells against K562 cells.…”

Section: Introductionmentioning

confidence: 99%

Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells

Zhang

Liu²,

et al. 2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Cytotoxic effect of trans-cinnamaldehyde on human leukemia K562 cells

Zhang

Liu²,

et al. 2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

“…There seems to be suggestion of such superiority in a few reported cases. 15 Here, we present our Phase I/II clinical study on the use of allogeneic CIK cells for patients who have failed conventional DLI to explore the efficacy of CIK cells in the presence of DLI failure and define the role of CIK cells in the management of relapse post-allo-HSCT.…”

Section: Introductionmentioning

confidence: 99%

“…Feasibility and safety were shown, as well as efficacy in some cases. 15 One major concern is the possibility of more severe GVHD associated with the infusion of T cells activated in vitro. This seems not to be the case with the limited reports currently available.…”

Section: Introductionmentioning

confidence: 99%

“…10,11 Potent in vitro cytotoxicity against various chemo-resistant tumour cell lines, 12 lymphoma, 10,11 and primary AML 13 and CML cells 14 had been reported. CIK cells 15,16 and other ex vivo expanded polyclonal T cells 17 have been used as an activated form of DLI in the post-allo-HSCT setting. Feasibility and safety were shown, as well as efficacy in some cases.…”

Section: Introductionmentioning

confidence: 99%

“…This seems not to be the case with the limited reports currently available. [15][16][17] On the other hand, whether activated donor T cells are superior to unmanipulated donor lymphocytes is an important question.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies

Niam

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

We performed a Phase I/II clinical trial to study the feasibility, toxicity and efficacy of allogeneic cytokineinduced killer (CIK) cell expansion, and treatment for patients with haematological malignancies who relapsed after allogeneic haemopoietic SCT (allo-HSCT). Allogeneic CIK cells were successfully generated for a total of 24 patients, including those from patients' own leukapheresis products in 5 patients who had no access to further donor cells. The median CD3 þ T-cell expansion was 9.33 (1.3-38.97) fold, and CD3 þ CD56 þ natural killer (NK)-like T-cell expansion was 27.77 (2.59-438.93) fold. A total of 55 infusions were done for 16 patients who had either failed or progressed after initial response to various individualized chemotherapy regimens and donor lymphocyte infusion (DLI), at doses ranging from 10 to 200 million CD3 þ cells/kg. Response attributable to CIK cell infusion was observed in five patients. These included two with ALL, two with Hodgkin's disease (HD) and one with AML, and two of whom had a response sustained for more than 2 years. Acute GVHD occurred in three and was easily treatable. This study provides some evidence suggestive of the efficacy of allogeneic CIK cells even after failure of DLI in some cases.

show abstract